BMO Capital Reiterates Neurocrine (NBIX) at Outperform, But Notes Post-Pandemic Headwinds to Achieving Guidance
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $69.00 price target on Neurocrine Bio. (NASDAQ: NBIX) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
